These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37379865)

  • 1. AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
    Fragoso DC; Salles LMOP; Pereira SLA; Callegaro D; Sato DK; Rimkus CM
    Arq Neuropsiquiatr; 2023 Jun; 81(6):533-543. PubMed ID: 37379865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
    Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
    Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
    Sechi E; Krecke KN; Messina SA; Buciuc M; Pittock SJ; Chen JJ; Weinshenker BG; Lopez-Chiriboga AS; Lucchinetti CF; Zalewski NL; Tillema JM; Kunchok A; Monaco S; Morris PP; Fryer JP; Nguyen A; Greenwood T; Syc-Mazurek SB; Keegan BM; Flanagan EP
    Neurology; 2021 Sep; 97(11):e1097-e1109. PubMed ID: 34261784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.
    Lin L; Wu Y; Hang H; Lu J; Ding Y
    Front Immunol; 2022; 13():853891. PubMed ID: 35898513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
    Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
    Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG
    Xiao J; Zhang SQ; Chen X; Tang Y; Chen M; Shang K; Deng G; Qin C; Tian DS
    Mult Scler Relat Disord; 2022 Oct; 66():104057. PubMed ID: 35870369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
    Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
    Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
    Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD.
    Hyun JW; Lee HL; Park J; Kim J; Min JH; Kim BJ; Kim SW; Shin HY; Huh SY; Kim W; Seo JW; Kim KH; Kim SH; Kim HJ
    Mult Scler; 2022 May; 28(6):989-992. PubMed ID: 34865555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified models to distinguish central nervous system demyelinating diseases with brain lesions.
    Chen B; Qin C; Ji S; Tian D; Zhang M; Bu B
    Mult Scler Relat Disord; 2021 Jul; 52():102965. PubMed ID: 33905981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional spinal cord volumes and pain profiles in AQP4-IgG + NMOSD and MOGAD.
    Asseyer S; Zmira O; Busse L; Pflantzer B; Schindler P; Schmitz-Hübsch T; Paul F; Chien C
    Front Neurol; 2024; 15():1308498. PubMed ID: 38343712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
    Xie H; Shao Y; Du J; Song Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y
    J Neurol; 2022 Mar; 269(3):1641-1650. PubMed ID: 34383114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.
    Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
    J Neurol Sci; 2022 Jun; 437():120269. PubMed ID: 35483239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Brier MR; Wu GF; Chahin S; Cross AH; Naismith RT
    Mult Scler; 2022 Jan; 28(1):49-60. PubMed ID: 33870786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.
    Redenbaugh V; Chia NH; Cacciaguerra L; McCombe JA; Tillema JM; Chen JJ; Lopez Chiriboga AS; Sechi E; Hacohen Y; Pittock SJ; Flanagan EP
    Mult Scler; 2023 Jun; 29(7):799-808. PubMed ID: 37218499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative analysis of demographic, clinical and imaging features of myelin oligodendrocyte glycoprotein antibody positive, aquaporin 4 antibody positive, and double seronegative demyelinating disorders - An Indian tertiary care center prospective study.
    Salunkhe M; Gupta P; Singh RK; Elavarasi A; Vibha D; Garg A; Bhatia R; Tripathi M
    J Neurosci Rural Pract; 2023; 14(2):313-319. PubMed ID: 37181191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.